activins has been researched along with stilbenes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, ST; Cox, AG; Gurusinghe, S; Leaw, B; Lim, R; Marshall, SA; Mockler, JC; Muljadi, R; Murthi, P; Rahman, R; Singh, H; Wallace, EM | 1 |
| Devarakonda, PM; Goldhamer, DJ; Lees-Shepard, JB; Nicholas, SE; Schneider, MJ; Stoessel, SJ; Yamamoto, M | 1 |
2 other study(ies) available for activins and stilbenes
| Article | Year |
|---|---|
Resveratrol mitigates trophoblast and endothelial dysfunction partly via activation of nuclear factor erythroid 2-related factor-2.
Topics: Activins; Antioxidants; Endothelial Cells; Female; Heme Oxygenase-1; Human Umbilical Vein Endothelial Cells; Humans; NF-E2-Related Factor 2; Oxidative Stress; Pre-Eclampsia; Pregnancy; Resveratrol; Stilbenes; Trophoblasts; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Topics: Activin Receptors, Type I; Activins; Animals; Bone and Bones; Cell Differentiation; Chondrogenesis; Joints; Luminescent Measurements; Mice; Myositis Ossificans; Ossification, Heterotopic; Osteochondroma; Osteogenesis; Pyrazoles; Receptor, Platelet-Derived Growth Factor alpha; Stilbenes; Survival Analysis | 2018 |